Combination Studies With The Vascular Disrupting Agent CA4P

This work represents studies carried out at Mount Vernon Hospital and UCL, and sponsored by Cancer Research UK, between 2003 and 2006. Phase I/II Clinical trial studies of the vascular disrupting agent Combretastatin A4 Phosphate (CA4P) are presented - in combination with cytotoxic chemotherapy (Paclitaxel and Carboplatin), and radioimmunotherapy. Dynamic Contrast Enhanced MRI data from the studies is presented and discussed, and a supporting immunohistochemistry correlation study of vascular markers is also presented.

Autorentext

Dr Gaya is a Clinical Oncologist at Guy's and St Thomas' Hospitals in London. He has completed an MD at UCL of which this work is a summary. He treats patients with GI cancers and is continuing to pursue an interest in functional imaging of cancers.